Testicular Germ Cell Tumor

MONDO:0010108 Pathograph 3 gonadal germ cell tumor neoplasm of testis

Testicular germ cell tumors (TGCTs) are the most common solid malignancies in young men aged 15-35 years. They arise from primordial germ cells and are broadly classified into seminomas and non-seminomatous germ cell tumors (NSGCTs), which include embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. A hallmark cytogenetic abnormality is isochromosome 12p [i(12p)], present in virtually all cases. Seminomas frequently harbor KIT and KRAS mutations. TGCTs are highly chemosensitive, with cisplatin-based regimens (particularly BEP: bleomycin, etoposide, cisplatin) achieving cure rates exceeding 80% even in metastatic disease. Serum tumor markers (AFP, beta-hCG, LDH) are critical for diagnosis, staging, and monitoring treatment response, though circulating miR-371a-3p is emerging as a superior biomarker.

Ask OpenScientist

Ask a research question about Testicular Germ Cell Tumor. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
4
Phenotypes
3
Pathograph
4
Genes
5
Treatments
5
Subtypes
1
Deep Research
◆

Subtypes

5
Seminoma
50-55%
Pure seminoma accounts for approximately 50-55% of TGCTs. It arises from undifferentiated germ cells, is characterized by sheets of uniform cells with clear cytoplasm and central nuclei, and frequently contains lymphocytic infiltrates. Seminomas are highly radiosensitive and chemosensitive with excellent prognosis. Seminoma expresses an iPSC panel with OCT4/POU5F1, SOX17, KLF4, and MYC.
Show evidence (1 reference)
PMID:36835562 SUPPORT
"a seminoma subtype expresses an induced pluripotent stem cell (iPSC) panel with four upregulated genes, OCT4/POU5F1, SOX17, KLF4, and MYC"
Confirms the pluripotency gene expression panel characteristic of seminoma subtype.
Embryonal Carcinoma
20-40% as component
Embryonal carcinoma is a highly aggressive NSGCT component showing primitive epithelial differentiation. It can differentiate into other germ cell tumor types and is commonly found as a component of mixed germ cell tumors. EC expresses OCT4/POU5F1, SOX2, LIN28, and NANOG and can reprogram cells into iPSC.
Show evidence (1 reference)
PMID:36835562 SUPPORT
"embryonal carcinoma (EC) has four upregulated genes, OCT4/POU5F1, SOX2, LIN28, and NANOG. The EC panel can reprogram cells into iPSC, and both iPSC and EC can differentiate into teratoma"
Confirms EC pluripotency markers and its differentiation potential into teratoma.
Yolk Sac Tumor
Yolk sac tumor (endodermal sinus tumor) recapitulates extraembryonic yolk sac structures. It is the most common testicular tumor in prepubertal boys and produces alpha-fetoprotein (AFP). Schiller-Duval bodies are pathognomonic.
Choriocarcinoma
1-3%
Choriocarcinoma is a rare but highly aggressive NSGCT that shows trophoblastic differentiation with syncytiotrophoblasts and cytotrophoblasts. It produces high levels of beta-hCG and has a propensity for early hematogenous metastasis.
Teratoma
Teratoma contains well-differentiated tissues from two or three germ layers (ectoderm, mesoderm, endoderm). In postpubertal males, mature teratoma is considered malignant due to potential for somatic-type malignant transformation. Teratomas are chemoresistant and require surgical resection.
⚙

Pathophysiology

6
Germ Cell Neoplasia In Situ (GCNIS)
Nearly all postpubertal TGCTs arise from germ cell neoplasia in situ (GCNIS, formerly carcinoma in situ or intratubular germ cell neoplasia unclassified). GCNIS cells resemble fetal gonocytes that failed to mature normally during embryonic development. The initiating malignant transformation most likely occurs in utero in primordial germ cells/gonocytes. GCNIS cells can remain dormant until puberty and then accumulate chromosomal abnormalities that drive malignant progression.
primordial germ cell link
germ cell development link ⚠ ABNORMAL
Downstream
Isochromosome 12p and Genomic Amplification GCNIS acquires i(12p) during progression to invasive tumor
Show evidence (2 references)
PMID:38541652 SUPPORT Human Clinical
"the genetic and epigenetic factors involved in the pathogenesis of testicular germ cell tumors (TGCTs)"
This review describes the developmental origin of TGCTs from PGCs through genetic and epigenetic alterations.
PMID:38791003 SUPPORT Human Clinical
"epigenetics has recently come into the spotlight as a major factor in TGCT initiation, progression, and even resistance to treatment"
Supports epigenetic mechanisms underlying GCNIS formation and TGCT progression.
Isochromosome 12p and Genomic Amplification
Isochromosome 12p [i(12p)] is the most consistent cytogenetic abnormality in TGCTs, present in more than 80% of cases. The remaining cases show 12p overrepresentation through other mechanisms. The short arm of chromosome 12 harbors genes including KRAS, CCND2 (cyclin D2), NANOG, and LDHB that drive tumor proliferation and maintain pluripotency.
cell population proliferation link ↑ INCREASED chromosome organization link ⚠ ABNORMAL
Downstream
KIT/RAS Signaling Activation Amplified KRAS on 12p contributes to signaling activation
Show evidence (1 reference)
PMID:36835562 SUPPORT Human Clinical
"Epigenetic mechanisms, such as methylations of cytosines on the DNA string and methylations and acetylations of histone 3 lysines, regulate expression of these driver genes between the TGCT subtypes"
Supports the role of 12p-located driver genes (including NANOG) in TGCT tumorigenesis through epigenetic regulation.
KIT/RAS Signaling Activation
Activating mutations in KIT and K-RAS are the most significantly mutated somatic genes in TGCTs. KIT mutations are found in approximately 18-25% of TGCTs, predominantly in seminomas, and activate the RAS-RAF-MEK-ERK and PI3K-AKT signaling pathways, promoting cell survival and proliferation.
MAPK cascade link ↑ INCREASED phosphatidylinositol 3-kinase signaling link ↑ INCREASED
Show evidence (1 reference)
PMID:38541652 SUPPORT Human Clinical
"several genomic and transcriptomic assays have identified a few significantly mutated somatic genes, primarily KIT and K-RAS"
Confirms KIT and K-RAS as the primary significantly mutated somatic genes in TGCTs.
Cisplatin Sensitivity and DNA Damage Response
TGCTs are exquisitely sensitive to cisplatin-based chemotherapy due to several factors: limited DNA repair capacity, wild-type TP53 in most cases enabling robust apoptotic response, and high expression of pro-apoptotic factors (Bax, Noxa) with low expression of anti-apoptotic factors (Bcl-2). Both the death receptor (FAS/FASL) and mitochondrial apoptotic pathways become strongly activated following cisplatin treatment.
apoptotic process link ↑ INCREASED nucleotide-excision repair link ↓ DECREASED
Show evidence (3 references)
PMID:37891379 SUPPORT In Vitro
"metastatic testicular germ cell tumors (TGCT) are cured in over 80% of patients using cisplatin-based combination therapy. Published data suggest that TGCTs are sensitive to cisplatin due to limited DNA repair and presumably also to a propensity to undergo apoptosis"
Directly supports the dual mechanism of cisplatin sensitivity - limited DNA repair and strong apoptotic propensity in TGCTs.
PMID:37891379 SUPPORT In Vitro
"both the death receptor and the mitochondrial apoptotic pathway become strongly activated in TTC following cisplatin treatment, explaining, together with attenuated DNA repair, their unique sensitivity toward platinum-based anticancer drugs"
Confirms both death receptor and mitochondrial apoptotic pathways are activated in cisplatin-treated testis tumor cells.
PMID:37175579 SUPPORT Human Clinical
"Testicular germ-cell tumors (TGCT) have been widely recognized for their outstanding survival rates, commonly attributed to their high sensitivity to cisplatin-based therapies"
Confirms the clinical observation of high cisplatin sensitivity and outstanding survival rates in TGCT.
Cisplatin Resistance Mechanisms
Approximately 15% of TGCT patients develop platinum-refractory disease. Resistance mechanisms include epigenetic rewiring (DNA hypermethylation, H3K27me3 dynamics), upregulation of DNA repair pathways (ERCC1/XPF), suppression of apoptotic signaling, and overactivation of the neddylation pathway promoting degradation of tumor suppressors. CRISPR screening has identified NAE1 overexpression as a resistance factor, and its inhibition by MLN4924 can resensitize resistant cells to cisplatin.
response to drug link ⚠ ABNORMAL
Show evidence (3 references)
PMID:38275869 SUPPORT Human Clinical
"approximately 15% of the patients develop platinum-refractory disease and suffer multiple relapses"
Confirms the ~15% rate of cisplatin resistance in TGCT patients.
PMID:37024667 SUPPORT In Vitro
"We identified overactivation of neddylation as a factor for cisplatin resistance in TGCTs and highlighted the additive effect of NAE1 inhibition by MLN4924 in combination with cisplatin as a novel treatment option for TGCTs"
CRISPR screen identifies neddylation/NAE1 as a cisplatin resistance mechanism and MLN4924 as a potential therapeutic agent.
PMID:37175579 SUPPORT Human Clinical
"a subset of patients develops cisplatin resistance, for whom additional therapeutic options are unsuccessful, and ~20% of them will die from disease progression at an early age"
Confirms that a subset of TGCT patients develops cisplatin resistance with poor prognosis.
Epigenetic Regulation of Subtype Identity
DNA methylation is a primary determinant of TGCT subtype identity. GCNIS and seminomas are characterized by global DNA hypomethylation resembling fetal gonocytes, while non-seminomas show progressive hypermethylation associated with differentiation. Embryonal carcinoma exhibits an ESC-like methylation pattern. This epigenetic divergence underlies the distinct biology and treatment responses of TGCT subtypes.
DNA methylation link ↕ DYSREGULATED
Show evidence (2 references)
PMID:38791003 SUPPORT Human Clinical
"DNA methylation was the first revelation in this particular field, and it continues to be a main target of investigations as research into its association with TGCT has contributed to a better understanding of this type of cancer"
Confirms the central role of DNA methylation in TGCT pathogenesis and subtype differentiation.
PMID:36835562 SUPPORT Human Clinical
"Epigenetic mechanisms, such as methylations of cytosines on the DNA string and methylations and acetylations of histone 3 lysines, regulate expression of these driver genes between the TGCT subtypes"
Confirms epigenetic mechanisms regulate driver gene expression differences between TGCT subtypes.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Testicular Germ Cell Tumor Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Breast 1
Gynecomastia VERY_RARE Gynecomastia (HP:0000771)
Genitourinary 2
Testicular Mass OBLIGATE Testicular neoplasm (HP:0010788)
Show evidence (1 reference)
PMID:37820296 SUPPORT Human Clinical
"Testicular GCTs (TGCTs) are the most common cancers in 15- to 39-year-old men"
Confirms TGCTs are the most common cancers in young adult men.
Cryptorchidism (Risk Factor) Cryptorchidism (HP:0000028)
Metabolism 1
Elevated Serum Alpha-Fetoprotein OCCASIONAL Elevated circulating alpha-fetoprotein concentration (HP:0006254)
🧬

Genetic Associations

4
KIT (Activating mutations in ~18-25% of TGCTs, primarily seminomas)
Show evidence (1 reference)
PMID:38541652 SUPPORT Human Clinical
"several genomic and transcriptomic assays have identified a few significantly mutated somatic genes, primarily KIT and K-RAS"
Identifies KIT as one of the primary significantly mutated genes in TGCTs.
KRAS (Activating mutations in ~14-26% of TGCTs)
Show evidence (1 reference)
PMID:38541652 SUPPORT Human Clinical
"several genomic and transcriptomic assays have identified a few significantly mutated somatic genes, primarily KIT and K-RAS"
Identifies K-RAS as one of the primary significantly mutated genes in TGCTs.
Isochromosome 12p (Present in >80% of TGCTs)
TP53 (Wild-type in most TGCTs; mutations in ~10-17% of refractory cases)
Show evidence (1 reference)
PMID:37891379 SUPPORT In Vitro
"Immunoblotting experiments revealed p53 to be induced in TTC, but not bladder cancer cells following cisplatin"
Demonstrates functional p53 induction in testis tumor cells after cisplatin treatment, consistent with wild-type p53 in most TGCTs.
💊

Treatments

5
Radical Inguinal Orchiectomy
Action: radical orchiectomy Ontology label: surgical procedure MAXO:0000004
Radical inguinal orchiectomy is the primary diagnostic and therapeutic procedure for all suspected testicular tumors. It provides tissue for histological diagnosis and pathological staging. Trans-scrotal biopsy is contraindicated due to risk of tumor seeding.
BEP Chemotherapy
Action: BEP chemotherapy Ontology label: chemotherapy MAXO:0000647
Bleomycin, etoposide, and cisplatin (BEP) is the standard first-line chemotherapy regimen for metastatic TGCT. Cisplatin-based chemotherapy cures over 80% of metastatic cases. Three cycles for good-risk and four cycles for intermediate/poor-risk disease.
Show evidence (2 references)
PMID:37891379 SUPPORT In Vitro
"metastatic testicular germ cell tumors (TGCT) are cured in over 80% of patients using cisplatin-based combination therapy"
Confirms the >80% cure rate with cisplatin-based combination therapy for metastatic TGCT.
PMID:37820296 SUPPORT Human Clinical
"Excellent outcomes, even in widely metastatic disease using cisplatin-based chemotherapy, can be achieved since Einhorn and Donohue's landmark 1977 study in TGCT"
Confirms excellent outcomes with cisplatin-based chemotherapy in metastatic TGCT.
Surveillance
Action: active surveillance Ontology label: supportive care MAXO:0000950
Active surveillance is an option for stage I TGCT after orchiectomy, involving regular monitoring with tumor markers, imaging, and physical examination. In a prospective cohort, 15.1% of stage I patients relapsed on surveillance, all of whom were salvageable.
Show evidence (1 reference)
PMID:37967143 SUPPORT Human Clinical
"258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques"
Describes prospective surveillance protocol for stage I TGCT.
Radiation Therapy
Action: radiation therapy MAXO:0000014
Adjuvant radiation therapy to para-aortic lymph nodes is an option for stage I and IIA seminoma. It has largely been replaced by single-agent carboplatin or surveillance in stage I disease.
Retroperitoneal Lymph Node Dissection (RPLND)
Action: retroperitoneal lymph node dissection Ontology label: surgical procedure MAXO:0000004
RPLND is used for staging and treatment of residual retroperitoneal masses after chemotherapy, particularly for non-seminomatous tumors with residual disease. It is also a primary treatment option for stage I NSGCT.
🌍

Environmental Factors

2
Cryptorchidism
Undescended testis is the strongest established risk factor, conferring 4-8 fold increased risk of TGCT.
Testicular Dysgenesis Syndrome
TGCTs may be part of testicular dysgenesis syndrome, a cluster of conditions including cryptorchidism, hypospadias, and impaired spermatogenesis, linked to disrupted fetal testicular development.
🔬

Biochemical Markers

4
Alpha-Fetoprotein (AFP) (Elevated in yolk sac tumor and embryonal carcinoma)
Beta-Human Chorionic Gonadotropin (beta-hCG) (Elevated in choriocarcinoma; mildly elevated in 10-15% of seminomas)
Lactate Dehydrogenase (LDH) (Elevated proportional to tumor burden)
microRNA-371a-3p (miR-371a-3p) (Elevated in serum of patients with viable non-teratomatous TGCT)
Show evidence (1 reference)
PMID:37967143 SUPPORT Human Clinical
"area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%"
Prospective multicenter study demonstrating superior diagnostic performance of miR-371a-3p for TGCT relapse detection.
{ }

Source YAML

click to show 
name: Testicular Germ Cell Tumor
creation_date: "2026-03-06T00:00:00Z"
updated_date: "2026-03-06T00:00:00Z"
description: >-
  Testicular germ cell tumors (TGCTs) are the most common solid malignancies in young men
  aged 15-35 years. They arise from primordial germ cells and are broadly classified into
  seminomas and non-seminomatous germ cell tumors (NSGCTs), which include embryonal carcinoma,
  yolk sac tumor, choriocarcinoma, and teratoma. A hallmark cytogenetic abnormality is
  isochromosome 12p [i(12p)], present in virtually all cases. Seminomas frequently harbor
  KIT and KRAS mutations. TGCTs are highly chemosensitive, with cisplatin-based regimens
  (particularly BEP: bleomycin, etoposide, cisplatin) achieving cure rates exceeding 80%
  even in metastatic disease. Serum tumor markers (AFP, beta-hCG, LDH) are critical for
  diagnosis, staging, and monitoring treatment response, though circulating miR-371a-3p
  is emerging as a superior biomarker.
categories:
- Germ Cell Neoplasm
- Solid Tumor
- Urologic Cancer
parents:
- gonadal germ cell tumor
- neoplasm of testis
disease_term:
  preferred_term: testicular germ cell tumor
  term:
    id: MONDO:0010108
    label: testicular germ cell tumor
has_subtypes:
- name: Seminoma
  description: >-
    Pure seminoma accounts for approximately 50-55% of TGCTs. It arises from
    undifferentiated germ cells, is characterized by sheets of uniform cells with
    clear cytoplasm and central nuclei, and frequently contains lymphocytic infiltrates.
    Seminomas are highly radiosensitive and chemosensitive with excellent prognosis.
    Seminoma expresses an iPSC panel with OCT4/POU5F1, SOX17, KLF4, and MYC.
  subtype_frequency: "50-55%"
  evidence:
  - reference: PMID:36835562
    reference_title: "Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis."
    supports: SUPPORT
    snippet: >-
      a seminoma subtype expresses an induced pluripotent stem cell (iPSC) panel
      with four upregulated genes, OCT4/POU5F1, SOX17, KLF4, and MYC
    explanation: >-
      Confirms the pluripotency gene expression panel characteristic of seminoma
      subtype.
- name: Embryonal Carcinoma
  description: >-
    Embryonal carcinoma is a highly aggressive NSGCT component showing primitive
    epithelial differentiation. It can differentiate into other germ cell tumor types
    and is commonly found as a component of mixed germ cell tumors. EC expresses
    OCT4/POU5F1, SOX2, LIN28, and NANOG and can reprogram cells into iPSC.
  subtype_frequency: "20-40% as component"
  evidence:
  - reference: PMID:36835562
    reference_title: "Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis."
    supports: SUPPORT
    snippet: >-
      embryonal carcinoma (EC) has four upregulated genes, OCT4/POU5F1, SOX2, LIN28,
      and NANOG. The EC panel can reprogram cells into iPSC, and both iPSC and EC can
      differentiate into teratoma
    explanation: >-
      Confirms EC pluripotency markers and its differentiation potential into
      teratoma.
- name: Yolk Sac Tumor
  description: >-
    Yolk sac tumor (endodermal sinus tumor) recapitulates extraembryonic yolk sac
    structures. It is the most common testicular tumor in prepubertal boys and produces
    alpha-fetoprotein (AFP). Schiller-Duval bodies are pathognomonic.
- name: Choriocarcinoma
  description: >-
    Choriocarcinoma is a rare but highly aggressive NSGCT that shows trophoblastic
    differentiation with syncytiotrophoblasts and cytotrophoblasts. It produces
    high levels of beta-hCG and has a propensity for early hematogenous metastasis.
  subtype_frequency: "1-3%"
- name: Teratoma
  description: >-
    Teratoma contains well-differentiated tissues from two or three germ layers
    (ectoderm, mesoderm, endoderm). In postpubertal males, mature teratoma is
    considered malignant due to potential for somatic-type malignant transformation.
    Teratomas are chemoresistant and require surgical resection.
pathophysiology:
- name: Germ Cell Neoplasia In Situ (GCNIS)
  description: >-
    Nearly all postpubertal TGCTs arise from germ cell neoplasia in situ (GCNIS,
    formerly carcinoma in situ or intratubular germ cell neoplasia unclassified).
    GCNIS cells resemble fetal gonocytes that failed to mature normally during
    embryonic development. The initiating malignant transformation most likely
    occurs in utero in primordial germ cells/gonocytes. GCNIS cells can remain
    dormant until puberty and then accumulate chromosomal abnormalities that
    drive malignant progression.
  evidence:
  - reference: PMID:38541652
    reference_title: "RAS/Mitogen-Activated Protein Kinase Signaling Pathway in Testicular Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the genetic and epigenetic factors involved in the pathogenesis of testicular
      germ cell tumors (TGCTs)
    explanation: >-
      This review describes the developmental origin of TGCTs from PGCs through
      genetic and epigenetic alterations.
  - reference: PMID:38791003
    reference_title: "Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      epigenetics has recently come into the spotlight as a major factor in TGCT
      initiation, progression, and even resistance to treatment
    explanation: >-
      Supports epigenetic mechanisms underlying GCNIS formation and TGCT progression.
  cell_types:
  - preferred_term: primordial germ cell
    term:
      id: CL:0000670
      label: primordial germ cell
  biological_processes:
  - preferred_term: germ cell development
    modifier: ABNORMAL
    term:
      id: GO:0007281
      label: germ cell development
  downstream:
  - target: Isochromosome 12p and Genomic Amplification
    description: GCNIS acquires i(12p) during progression to invasive tumor
- name: Isochromosome 12p and Genomic Amplification
  description: >-
    Isochromosome 12p [i(12p)] is the most consistent cytogenetic abnormality in
    TGCTs, present in more than 80% of cases. The remaining cases show 12p
    overrepresentation through other mechanisms. The short arm of chromosome 12
    harbors genes including KRAS, CCND2 (cyclin D2), NANOG, and LDHB that drive
    tumor proliferation and maintain pluripotency.
  evidence:
  - reference: PMID:36835562
    reference_title: "Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Epigenetic mechanisms, such as methylations of cytosines on the DNA string and
      methylations and acetylations of histone 3 lysines, regulate expression of these
      driver genes between the TGCT subtypes
    explanation: >-
      Supports the role of 12p-located driver genes (including NANOG) in TGCT
      tumorigenesis through epigenetic regulation.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  - preferred_term: chromosome organization
    modifier: ABNORMAL
    term:
      id: GO:0051276
      label: chromosome organization
  downstream:
  - target: KIT/RAS Signaling Activation
    description: Amplified KRAS on 12p contributes to signaling activation
- name: KIT/RAS Signaling Activation
  description: >-
    Activating mutations in KIT and K-RAS are the most significantly mutated somatic
    genes in TGCTs. KIT mutations are found in approximately 18-25% of TGCTs,
    predominantly in seminomas, and activate the RAS-RAF-MEK-ERK and PI3K-AKT
    signaling pathways, promoting cell survival and proliferation.
  evidence:
  - reference: PMID:38541652
    reference_title: "RAS/Mitogen-Activated Protein Kinase Signaling Pathway in Testicular Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      several genomic and transcriptomic assays have identified a few significantly
      mutated somatic genes, primarily KIT and K-RAS
    explanation: >-
      Confirms KIT and K-RAS as the primary significantly mutated somatic genes in
      TGCTs.
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  - preferred_term: phosphatidylinositol 3-kinase signaling
    modifier: INCREASED
    term:
      id: GO:0043491
      label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
- name: Cisplatin Sensitivity and DNA Damage Response
  description: >-
    TGCTs are exquisitely sensitive to cisplatin-based chemotherapy due to several
    factors: limited DNA repair capacity, wild-type TP53 in most cases enabling
    robust apoptotic response, and high expression of pro-apoptotic factors (Bax,
    Noxa) with low expression of anti-apoptotic factors (Bcl-2). Both the death
    receptor (FAS/FASL) and mitochondrial apoptotic pathways become strongly
    activated following cisplatin treatment.
  evidence:
  - reference: PMID:37891379
    reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      metastatic testicular germ cell tumors (TGCT) are cured in over 80% of patients
      using cisplatin-based combination therapy. Published data suggest that TGCTs are
      sensitive to cisplatin due to limited DNA repair and presumably also to a
      propensity to undergo apoptosis
    explanation: >-
      Directly supports the dual mechanism of cisplatin sensitivity - limited DNA
      repair and strong apoptotic propensity in TGCTs.
  - reference: PMID:37891379
    reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      both the death receptor and the mitochondrial apoptotic pathway become strongly
      activated in TTC following cisplatin treatment, explaining, together with
      attenuated DNA repair, their unique sensitivity toward platinum-based anticancer
      drugs
    explanation: >-
      Confirms both death receptor and mitochondrial apoptotic pathways are activated
      in cisplatin-treated testis tumor cells.
  - reference: PMID:37175579
    reference_title: "Breaking the Mold: Epigenetics and Genomics Approaches Addressing Novel Treatments and Chemoresponse in TGCT Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Testicular germ-cell tumors (TGCT) have been widely recognized for their
      outstanding survival rates, commonly attributed to their high sensitivity to
      cisplatin-based therapies
    explanation: >-
      Confirms the clinical observation of high cisplatin sensitivity and outstanding
      survival rates in TGCT.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  - preferred_term: nucleotide-excision repair
    modifier: DECREASED
    term:
      id: GO:0006289
      label: nucleotide-excision repair
- name: Cisplatin Resistance Mechanisms
  description: >-
    Approximately 15% of TGCT patients develop platinum-refractory disease.
    Resistance mechanisms include epigenetic rewiring (DNA hypermethylation,
    H3K27me3 dynamics), upregulation of DNA repair pathways (ERCC1/XPF),
    suppression of apoptotic signaling, and overactivation of the neddylation
    pathway promoting degradation of tumor suppressors. CRISPR screening has
    identified NAE1 overexpression as a resistance factor, and its inhibition
    by MLN4924 can resensitize resistant cells to cisplatin.
  evidence:
  - reference: PMID:38275869
    reference_title: "The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      approximately 15% of the patients develop platinum-refractory disease and
      suffer multiple relapses
    explanation: >-
      Confirms the ~15% rate of cisplatin resistance in TGCT patients.
  - reference: PMID:37024667
    reference_title: "Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We identified overactivation of neddylation as a factor for cisplatin resistance
      in TGCTs and highlighted the additive effect of NAE1 inhibition by MLN4924 in
      combination with cisplatin as a novel treatment option for TGCTs
    explanation: >-
      CRISPR screen identifies neddylation/NAE1 as a cisplatin resistance mechanism
      and MLN4924 as a potential therapeutic agent.
  - reference: PMID:37175579
    reference_title: "Breaking the Mold: Epigenetics and Genomics Approaches Addressing Novel Treatments and Chemoresponse in TGCT Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a subset of patients develops cisplatin resistance, for whom additional
      therapeutic options are unsuccessful, and ~20% of them will die from disease
      progression at an early age
    explanation: >-
      Confirms that a subset of TGCT patients develops cisplatin resistance with
      poor prognosis.
  biological_processes:
  - preferred_term: response to drug
    modifier: ABNORMAL
    term:
      id: GO:0009410
      label: response to xenobiotic stimulus
- name: Epigenetic Regulation of Subtype Identity
  description: >-
    DNA methylation is a primary determinant of TGCT subtype identity. GCNIS and
    seminomas are characterized by global DNA hypomethylation resembling fetal
    gonocytes, while non-seminomas show progressive hypermethylation associated
    with differentiation. Embryonal carcinoma exhibits an ESC-like methylation
    pattern. This epigenetic divergence underlies the distinct biology and
    treatment responses of TGCT subtypes.
  evidence:
  - reference: PMID:38791003
    reference_title: "Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DNA methylation was the first revelation in this particular field, and it
      continues to be a main target of investigations as research into its association
      with TGCT has contributed to a better understanding of this type of cancer
    explanation: >-
      Confirms the central role of DNA methylation in TGCT pathogenesis and subtype
      differentiation.
  - reference: PMID:36835562
    reference_title: "Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Epigenetic mechanisms, such as methylations of cytosines on the DNA string and
      methylations and acetylations of histone 3 lysines, regulate expression of
      these driver genes between the TGCT subtypes
    explanation: >-
      Confirms epigenetic mechanisms regulate driver gene expression differences
      between TGCT subtypes.
  biological_processes:
  - preferred_term: DNA methylation
    modifier: DYSREGULATED
    term:
      id: GO:0006304
      label: DNA modification
phenotypes:
- category: Neoplastic
  name: Testicular Mass
  frequency: OBLIGATE
  description: >-
    A painless or mildly painful testicular mass is the most common presenting
    symptom. TGCTs are the most common cancers in 15- to 39-year-old men.
  evidence:
  - reference: PMID:37820296
    reference_title: "Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Testicular GCTs (TGCTs) are the most common cancers in 15- to 39-year-old men
    explanation: >-
      Confirms TGCTs are the most common cancers in young adult men.
  phenotype_term:
    preferred_term: Testicular neoplasm
    term:
      id: HP:0010788
      label: Testicular neoplasm
- category: Neoplastic
  name: Elevated Serum Alpha-Fetoprotein
  frequency: OCCASIONAL
  description: >-
    AFP is elevated in yolk sac tumors and embryonal carcinoma but never in pure
    seminoma or pure choriocarcinoma. Elevated AFP in the setting of a testicular
    mass indicates non-seminomatous elements.
  phenotype_term:
    preferred_term: Elevated alpha-fetoprotein
    term:
      id: HP:0006254
      label: Elevated circulating alpha-fetoprotein concentration
- category: Clinical
  name: Gynecomastia
  frequency: VERY_RARE
  description: >-
    Gynecomastia may occur due to beta-hCG production by the tumor (especially
    choriocarcinoma), which stimulates estrogen production.
  phenotype_term:
    preferred_term: Gynecomastia
    term:
      id: HP:0000771
      label: Gynecomastia
- category: Clinical
  name: Cryptorchidism (Risk Factor)
  description: >-
    Cryptorchidism (undescended testis) is the strongest established risk factor
    for TGCT, increasing risk 4-8 fold. Orchiopexy before puberty reduces but
    does not eliminate the risk.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
biochemical:
- name: Alpha-Fetoprotein (AFP)
  presence: Elevated in yolk sac tumor and embryonal carcinoma
  notes: Never elevated in pure seminoma or pure choriocarcinoma
- name: Beta-Human Chorionic Gonadotropin (beta-hCG)
  presence: Elevated in choriocarcinoma; mildly elevated in 10-15% of seminomas
- name: Lactate Dehydrogenase (LDH)
  presence: Elevated proportional to tumor burden
  notes: Non-specific marker; reflects tumor volume; LDHB gene located on 12p
- name: microRNA-371a-3p (miR-371a-3p)
  presence: Elevated in serum of patients with viable non-teratomatous TGCT
  notes: >-
    Superior sensitivity (100%) and specificity (96.3%) compared to traditional
    markers; cannot detect teratoma
  evidence:
  - reference: PMID:37967143
    reference_title: "Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%,
      positive predictive value 83%, negative predictive value 100%
    explanation: >-
      Prospective multicenter study demonstrating superior diagnostic performance
      of miR-371a-3p for TGCT relapse detection.
genetic:
- name: KIT
  association: Activating mutations in ~18-25% of TGCTs, primarily seminomas
  features: Exon 11 and 17 mutations
  evidence:
  - reference: PMID:38541652
    reference_title: "RAS/Mitogen-Activated Protein Kinase Signaling Pathway in Testicular Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      several genomic and transcriptomic assays have identified a few significantly
      mutated somatic genes, primarily KIT and K-RAS
    explanation: >-
      Identifies KIT as one of the primary significantly mutated genes in TGCTs.
- name: KRAS
  association: Activating mutations in ~14-26% of TGCTs
  features: Codon 12 mutations; amplified via i(12p)
  evidence:
  - reference: PMID:38541652
    reference_title: "RAS/Mitogen-Activated Protein Kinase Signaling Pathway in Testicular Germ Cell Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      several genomic and transcriptomic assays have identified a few significantly
      mutated somatic genes, primarily KIT and K-RAS
    explanation: >-
      Identifies K-RAS as one of the primary significantly mutated genes in TGCTs.
- name: Isochromosome 12p
  association: Present in >80% of TGCTs
  features: >-
    Most consistent cytogenetic abnormality; harbors KRAS, CCND2, NANOG, LDHB
  notes: Pathognomonic for TGCT
- name: TP53
  association: Wild-type in most TGCTs; mutations in ~10-17% of refractory cases
  features: >-
    Wild-type p53 enables strong apoptotic response to cisplatin; mutations
    associated with cisplatin resistance
  evidence:
  - reference: PMID:37891379
    reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Immunoblotting experiments revealed p53 to be induced in TTC, but not bladder
      cancer cells following cisplatin
    explanation: >-
      Demonstrates functional p53 induction in testis tumor cells after cisplatin
      treatment, consistent with wild-type p53 in most TGCTs.
environmental:
- name: Cryptorchidism
  description: >-
    Undescended testis is the strongest established risk factor, conferring 4-8
    fold increased risk of TGCT.
  effect: Strong risk factor for TGCT development
- name: Testicular Dysgenesis Syndrome
  description: >-
    TGCTs may be part of testicular dysgenesis syndrome, a cluster of conditions
    including cryptorchidism, hypospadias, and impaired spermatogenesis, linked
    to disrupted fetal testicular development.
  effect: Associated developmental abnormalities sharing common etiology
treatments:
- name: Radical Inguinal Orchiectomy
  description: >-
    Radical inguinal orchiectomy is the primary diagnostic and therapeutic procedure
    for all suspected testicular tumors. It provides tissue for histological
    diagnosis and pathological staging. Trans-scrotal biopsy is contraindicated
    due to risk of tumor seeding.
  treatment_term:
    preferred_term: radical orchiectomy
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: BEP Chemotherapy
  description: >-
    Bleomycin, etoposide, and cisplatin (BEP) is the standard first-line
    chemotherapy regimen for metastatic TGCT. Cisplatin-based chemotherapy
    cures over 80% of metastatic cases. Three cycles for good-risk and four
    cycles for intermediate/poor-risk disease.
  evidence:
  - reference: PMID:37891379
    reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      metastatic testicular germ cell tumors (TGCT) are cured in over 80% of
      patients using cisplatin-based combination therapy
    explanation: >-
      Confirms the >80% cure rate with cisplatin-based combination therapy for
      metastatic TGCT.
  - reference: PMID:37820296
    reference_title: "Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Excellent outcomes, even in widely metastatic disease using cisplatin-based
      chemotherapy, can be achieved since Einhorn and Donohue's landmark 1977 study
      in TGCT
    explanation: >-
      Confirms excellent outcomes with cisplatin-based chemotherapy in metastatic
      TGCT.
  treatment_term:
    preferred_term: BEP chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
- name: Surveillance
  description: >-
    Active surveillance is an option for stage I TGCT after orchiectomy,
    involving regular monitoring with tumor markers, imaging, and physical
    examination. In a prospective cohort, 15.1% of stage I patients relapsed
    on surveillance, all of whom were salvageable.
  evidence:
  - reference: PMID:37967143
    reference_title: "Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      258 patients with testicular CSI GCT were prospectively followed by
      surveillance for a median time of 18 months with serial measurements of serum
      M371 levels, in addition to standard diagnostic techniques
    explanation: >-
      Describes prospective surveillance protocol for stage I TGCT.
  treatment_term:
    preferred_term: active surveillance
    term:
      id: MAXO:0000950
      label: supportive care
- name: Radiation Therapy
  description: >-
    Adjuvant radiation therapy to para-aortic lymph nodes is an option for
    stage I and IIA seminoma. It has largely been replaced by single-agent
    carboplatin or surveillance in stage I disease.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
- name: Retroperitoneal Lymph Node Dissection (RPLND)
  description: >-
    RPLND is used for staging and treatment of residual retroperitoneal masses
    after chemotherapy, particularly for non-seminomatous tumors with residual
    disease. It is also a primary treatment option for stage I NSGCT.
  treatment_term:
    preferred_term: retroperitoneal lymph node dissection
    term:
      id: MAXO:0000004
      label: surgical procedure
datasets:
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 60 citations 2026-03-06T03:57:47.086841

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Testicular Germ Cell Tumor
  • MONDO ID: (if available)
  • Category:

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Testicular Germ Cell Tumor. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Comprehensive Research Report: Pathophysiology of Testicular Germ Cell Tumor (TGCT)

0. Disease identifiers and scope

  • Disease name: Testicular germ cell tumor (TGCT)
  • Ontology IDs (from evidence): Open Targets disease ID EFO_1000566 (“Testicular Germ Cell Tumor”) (derived from Open Targets tool output; no MONDO ID was returned in the current context).
  • Category: Malignant neoplasm of the testis; predominantly germ cell histology (~90–95% of testicular cancers) (nicu2024recentadvancementsin pages 1-2, cuevasestrada2023breakingthemold pages 1-2).

TGCTs are clinically and molecularly dominated by post-pubertal, GCNIS-derived tumors. Multiple sources define TGCTs as arising from a precursor lesion, germ cell neoplasia in situ (GCNIS), and subdividing into seminoma and non-seminomatous germ cell tumor (NSGCT) subtypes (onorato2024rasmitogenactivatedproteinkinase pages 2-4, cuevasestrada2023breakingthemold pages 1-2, nicu2024recentadvancementsin pages 1-2).

1. Key concepts and definitions (current understanding)

1.1 Core definitions

  • TGCT: “Testicular germ cell tumors (TGCT)… are… unique in that they originate from the precursor lesion germ cell neoplasia in situ (GCNIS)” (Feb 2023 review) (eyben2023epigeneticregulationof pages 5-7).
  • Histologic groups: TGCTs are classified into seminoma (SE) and non-seminoma (NS), and non-seminomas include embryonal carcinoma (EC), yolk sac tumor, teratoma, and trophoblastic elements (onorato2024rasmitogenactivatedproteinkinase pages 2-4, cuevasestrada2023breakingthemold pages 1-2, nicu2024recentadvancementsin pages 1-2).
  • Precursor lesion (GCNIS): SE and NS “arise from a preinvasive lesion termed germ cell neoplasia in situ (GCNIS), which is composed of primordial germ cells arrested in maturation into gonocytes” (Apr 2023 review) (cuevasestrada2023breakingthemold pages 1-2).

1.2 Developmental origin and early lesion biology

A major concept is that TGCT is a developmental malignancy: initiating events occur in utero in primordial germ cells (PGCs)/gonocytes, producing GCNIS that can remain dormant until puberty. - “The initiating malignant transformation most likely occurs in utero” from “primordial germ cells/gonocytes” (Feb 2024 review) (onorato2024rasmitogenactivatedproteinkinase pages 2-4). - GCNIS cells can “remain dormant until puberty” and then accumulate chromosomal abnormalities that drive malignant progression to SE or EC (cuevasestrada2023breakingthemold pages 1-2).

1.3 Pathognomonic chromosomal hallmark

A cytogenetic hallmark of TGCT is gain of chromosome arm 12p, commonly as isochromosome 12p (i(12p)). - “Gain of the short arm of chromosome 12—often as isochromosome i(12p)—is… pathognomonic and present in >80% of cases” (Feb 2024 review) (onorato2024rasmitogenactivatedproteinkinase pages 2-4). - Independent evidence: i(12p) is “present in >80% of TGCTs” (Apr 2023 review) (cuevasestrada2023breakingthemold pages 2-4).

2. Core pathophysiology: molecular and cellular mechanisms

2.1 A unifying model

Across recent reviews and studies, TGCT pathophysiology can be summarized as: 1) Developmental arrest of PGCs/gonocytes with defective epigenetic reprogramming → 2) formation of GCNIS (pre-invasive, often globally hypomethylated) → 3) puberty-associated outgrowth and acquisition of chromosomal changes (notably 12p gain/i(12p), aneuploidy/tetraploidization) → 4) divergence into seminoma-like (PGC-like epigenome) vs EC/non-seminoma-like (pluripotent/ESC-like programs with lineage differentiation) → 5) invasion/metastasis, and in a subset, cisplatin resistance driven by DNA repair remodeling, apoptosis attenuation, and epigenetic rewiring.

Mechanistically supported components: - Early genome evolution: “tetraploidization is the first step” in TGCT tumorigenesis (Feb 2023 review) (eyben2023epigeneticregulationof pages 5-7). - Epigenetic divergence: “GCNIS… and seminomas… highly unmethylated like that of fetal gonocytes,” while NSGCTs show “hypermethylation pattern” (Jan 2024 review) (onorato2024rasmapksignalingpathway pages 5-7).

2.2 Dysregulated pathways

2.2.1 KIT/KITLG → RAS/RAF/MEK/ERK and PI3K/AKT

The KIT axis is central in germline biology and is recurrently altered in TGCT: - Exome data identify KIT (18–25%), K-RAS (14%), N-RAS (4%) predominantly in tumors with seminomatous components (Feb 2024 review) (onorato2024rasmitogenactivatedproteinkinase pages 5-7). - KIT is activated by KIT ligand/KITLG, triggering “RAS-RAF-MEK-ERK and PI3K/AKT signaling” (onorato2024rasmitogenactivatedproteinkinase pages 5-7).

2.2.2 Pluripotency circuitry and subtype identity

Subtype differences map strongly onto pluripotency programs: - EC shows pluripotency markers: EC is “strong immunohistochemical positivity for OCT4, SOX2 and LIN28” and negative for RB1 (eyben2023epigeneticregulationof pages 5-7). - 12p gain couples pluripotency and proliferation by amplifying CCND2 (cell cycle) and NANOG (pluripotency) (eyben2023epigeneticregulationof pages 5-7).

2.2.3 Epigenetic programming as a primary determinant

DNA methylation is emphasized as central to subtype identity: - “GCNIS and seminomas are characterized by global demethylation” and non-seminomas show differentiation-dependent methylation; embryonal carcinoma has ESC-like CpG and non-CpG methylation patterns (May 2024 review) (nicu2024recentadvancementsin pages 4-6). - The progression trend is explicit: “DNA methylation increases in the progression from GCNIS to differentiated NST subtypes” (Feb 2023 review) (eyben2023epigeneticregulationof pages 7-9).

3. Key molecular players (genes/proteins), chemicals, cell types, and anatomical locations

3.1 Ontology-ready entity map (knowledge-base ready)

Entity Type Specific Entity Name (Symbol/Term) Role in TGCT Pathophysiology Evidence/Notes Key Citations
Gene/Protein KIT (HGNC:6342) Proto-oncogene encoding RTK; mutations activate MAPK/PI3K pathways driving proliferation/survival. Mutated in ~18–25% of TGCTs (predominantly seminomas); 4q12 amplification also seen; drives platinum sensitivity when wild-type but mutations link to sensitivity. (cuevasestrada2023breakingthemold pages 2-4, onorato2024rasmitogenactivatedproteinkinase pages 1-2, onorato2024rasmitogenactivatedproteinkinase pages 5-7, onorato2024rasmapksignalingpathway pages 1-3)
Gene/Protein KITLG (HGNC:6343) Ligand for KIT; essential for PGC survival/migration; variants affect TGCT risk. 12q22 locus risk variant (rs4474514) associated with TGCT; crucial for PGC-to-GCNIS transition. (onorato2024rasmitogenactivatedproteinkinase pages 1-2, onorato2024rasmitogenactivatedproteinkinase pages 5-7, onorato2024rasmapksignalingpathway pages 1-3)
Gene/Protein KRAS (HGNC:6407) GTPase linking KIT/RTK to MAPK pathway; mutations drive proliferation/survival. Mutated in ~14–26% of TGCTs; often codon 12 mutations; associated with seminomatous components. (onorato2024rasmitogenactivatedproteinkinase pages 1-2, cuevasestrada2023breakingthemold pages 2-4, onorato2024rasmitogenactivatedproteinkinase pages 5-7, onorato2024rasmitogenactivatedproteinkinase pages 7-9)
Gene/Protein NRAS (HGNC:7989) GTPase in MAPK pathway; mutations drive oncogenic signaling. Mutated in ~4% of TGCTs; enriched in seminomatous tumors. (cuevasestrada2023breakingthemold pages 2-4, onorato2024rasmitogenactivatedproteinkinase pages 5-7, onorato2024rasmitogenactivatedproteinkinase pages 7-9)
Gene/Protein CCND2 (HGNC:1583) G1/S-specific cyclin D2; regulates cell cycle progression. Located on 12p (12p13.32); overexpression driven by 12p gain promotes proliferation. (eyben2023epigeneticregulationof pages 5-7, eyben2023epigeneticregulationof pages 21-22)
Gene/Protein NANOG (HGNC:20857) Pluripotency transcription factor; maintains stemness/undifferentiated state. Located on 12p (12p13.31); high expression in seminoma/EC; linked to stemness and cisplatin sensitivity. (eyben2023epigeneticregulationof pages 5-7, nicu2024recentadvancementsin pages 4-6, cuevasestrada2023breakingthemold pages 8-10)
Gene/Protein LDHB (HGNC:6541) Lactate dehydrogenase B; involved in metabolic reprogramming (Warburg effect). Located on 12p; amplification/overexpression linked to elevated serum LDH (biomarker). (eyben2023epigeneticregulationof pages 5-7)
Gene/Protein DNMT3B (HGNC:2979) DNA methyltransferase 3B; de novo methylation. Overexpressed in non-seminomas/EC; regulates H3K27me3/EZH2 crosstalk; linked to cisplatin resistance. (nicu2024recentadvancementsin pages 10-11, nicu2024recentadvancementsin pages 2-4, cuevasestrada2023breakingthemold pages 17-19)
Gene/Protein EZH2 (HGNC:3528) Histone methyltransferase (H3K27me3); regulates gene silencing/differentiation. Higher expression in non-seminoma/EC; loss of H3K27me3 promotes cisplatin resistance; EZH2 inhibition may induce resistance. (eyben2023epigeneticregulationof pages 7-9, cuevasestrada2023breakingthemold pages 17-19)
Gene/Protein RB1 (HGNC:9884) Tumor suppressor; regulates G1/S transition. Loss of RB1 expression is characteristic of embryonal carcinoma (EC) and links to pluripotency. (eyben2023epigeneticregulationof pages 5-7, eyben2023epigeneticregulationof pages 21-22)
Gene/Protein CDKN2A/CDKN1A (HGNC:1787/1784) Cyclin-dependent kinase inhibitors (p16/p21); regulate cell cycle arrest. Downregulated in TGCT, promoting proliferation; p21 induction by p53 is key for cisplatin response (arrest/apoptosis). (eyben2023epigeneticregulationof pages 5-7, eyben2023epigeneticregulationof pages 21-22, cuevasestrada2023breakingthemold pages 8-10)
Gene/Protein ERCC1/XPA/XPF (HGNC:3433/12814/3436) Nucleotide excision repair (NER) proteins; repair cisplatin-DNA adducts. Low expression in sensitive TGCTs leads to repair deficiency; overexpression correlates with cisplatin resistance. (funke2023genomescalecrisprscreen pages 11-12, cuevasestrada2023breakingthemold pages 6-8, cuevasestrada2023breakingthemold pages 8-10, koberle2024strongapoptoticresponse pages 1-2)
Gene/Protein REV7 (MAD2L2) (HGNC:6764) DNA repair protein (TLS/NHEJ); modulator of cisplatin sensitivity. Loss/inactivation increases DSB accumulation and restores cisplatin sensitivity in resistant cells. (cuevasestrada2023breakingthemold pages 29-30, cuevasestrada2023breakingthemold pages 6-8, cuevasestrada2023breakingthemold pages 5-6)
Gene/Protein MDM2 (HGNC:6973) E3 ubiquitin ligase; negative regulator of p53. Amplification (CNV gain) or overexpression inhibits p53-mediated apoptosis, driving cisplatin resistance. (cuevasestrada2023breakingthemold pages 29-30, funke2023genomescalecrisprscreen pages 11-12, cuevasestrada2023breakingthemold pages 5-6)
Gene/Protein TP53 (HGNC:11998) Tumor suppressor; master regulator of apoptosis following DNA damage. Wild-type in most TGCTs (drives high apoptotic sensitivity); mutations (~10–17% in refractory) cause resistance. (cuevasestrada2023breakingthemold pages 8-10, koberle2024strongapoptoticresponse pages 1-2, koberle2024strongapoptoticresponse pages 8-9)
Gene/Protein NAE1 (HGNC:7634) NEDD8-activating enzyme E1; initiates neddylation pathway. Overexpressed in resistant TGCTs; inhibition (MLN4924) stabilizes p21/p27/NOXA and restores cisplatin sensitivity. (funke2023genomescalecrisprscreen pages 11-12)
Pathway/Process 12p Gain / Isochromosome 12p (GO:0000000) Chromosomal instability/aneuploidy hallmark; amplifies drivers. Present in >80% of TGCTs; pathognomonic early event; amplifies CCND2, NANOG, KRAS, LDHB. (eyben2023epigeneticregulationof pages 5-7, onorato2024rasmapksignalingpathway pages 3-5, onorato2024rasmitogenactivatedproteinkinase pages 2-4, cuevasestrada2023breakingthemold pages 2-4)
Pathway/Process DNA Methylation Reprogramming (GO:0044728) Epigenetic erasure and re-establishment during germline development. Global hypomethylation in GCNIS/seminoma (resembling PGCs); hypermethylation in non-seminoma (differentiation). (nicu2024recentadvancementsin pages 2-4, nicu2024recentadvancementsin pages 4-6, eyben2023epigeneticregulationof pages 7-9, nicu2024recentadvancementsin pages 10-11)
Pathway/Process MAPK Cascade (GO:0000165) Signaling pathway regulating proliferation and survival. Dysregulated by KIT/KRAS mutations; constitutively activated ERK in many TGCTs; potential therapeutic target. (onorato2024rasmapksignalingpathway pages 3-5, onorato2024rasmitogenactivatedproteinkinase pages 2-4, onorato2024rasmitogenactivatedproteinkinase pages 5-7, onorato2024rasmitogenactivatedproteinkinase pages 7-9)
Pathway/Process Apoptosis (FAS/BAX/NOXA) (GO:0006915) Programmed cell death; primary mechanism of cisplatin cure. TGCTs are "primed" for apoptosis (high BAX/NOXA, low BCL2); p53 upregulates FAS/FASL (extrinsic) and mitochondrial (intrinsic) pathways. (cuevasestrada2023breakingthemold pages 8-10, koberle2024strongapoptoticresponse pages 1-2, koberle2024strongapoptoticresponse pages 8-9)
Pathway/Process NER / HR DNA Repair (GO:0006289/0000724) Repair of cisplatin-induced interstrand crosslinks. Intrinsic deficiency (low ERCC1/XPF) confers sensitivity; upregulation/restoration causes resistance. (cuevasestrada2023breakingthemold pages 6-8, cuevasestrada2023breakingthemold pages 8-10, koberle2024strongapoptoticresponse pages 1-2)
Pathway/Process Neddylation (GO:0045116) Post-translational modification conjugating NEDD8 to substrates. Overactive in resistant TGCTs; promotes degradation of tumor suppressors; targetable by NAE1 inhibitors. (funke2023genomescalecrisprscreen pages 11-12)
Biomarker AFP (Alpha-fetoprotein) (HP:0006255) Serum tumor marker for yolk sac/embryonal elements. Elevated in non-seminomas (~44–60%); not produced by pure seminoma; low sensitivity for relapse (~40%). (sykes2024currentandevolving pages 1-2, belge2024detectionofrecurrence pages 1-2, seales2024advancinggctmanagement pages 2-3, sykes2024currentandevolving pages 2-4)
Biomarker Beta-hCG (HP:0003153) Serum tumor marker (syncytiotrophoblastic cells). Elevated in ~30% of seminomas and ~50% of non-seminomas; limited sensitivity for relapse. (sykes2024currentandevolving pages 1-2, belge2024detectionofrecurrence pages 1-2, sykes2024currentandevolving pages 2-4)
Biomarker LDH (Lactate dehydrogenase) (HP:0003250) Non-specific marker of tumor burden/turnover. Least specific; elevated in ~30–40% of advanced cases; encoded by LDHB on 12p. (eyben2023epigeneticregulationof pages 5-7, sykes2024currentandevolving pages 1-2, sykes2024currentandevolving pages 2-4)
Biomarker miR-371a-3p (NCIT:C106727) Circulating microRNA; novel high-performance biomarker. Sensitivity >90%, Specificity >94% (superior to AFP/hCG); detects viable GCT (not teratoma); relapse detection AUC 0.99. (seales2024advancinggctmanagement pages 3-5, belge2024detectionofrecurrence pages 2-3, sykes2024currentandevolving pages 1-2, belge2024detectionofrecurrence pages 1-2, yodkhunnatham2024micrornasintesticular pages 3-5)
Chemical/Drug Cisplatin (CHEBI:27899) Platinum-based chemotherapy agent; standard of care. Highly effective due to TGCT hypersensitivity (DNA adducts $\to$ apoptosis); cure rate >90% in good risk; resistance in ~15%. (cuevasestrada2023breakingthemold pages 6-8, koberle2024strongapoptoticresponse pages 1-2, koberle2024strongapoptoticresponse pages 8-9, evmorfopoulos2024theimmunelandscape pages 1-2)
Chemical/Drug MLN4924 (Pevonedistat) (CHEBI:95577) NAE1 inhibitor (neddylation inhibitor). Sensitizes resistant TGCT cells to cisplatin by accumulating p21/p27/NOXA; experimental therapeutic. (funke2023genomescalecrisprscreen pages 11-12)
Chemical/Drug 5-Azacytidine / Decitabine (CHEBI:28902) DNMT inhibitors (hypomethylating agents). "Epigenetic priming"; restore sensitivity in resistant embryonal carcinoma by reversing hypermethylation (e.g., DNMT3B targets). (nicu2024recentadvancementsin pages 10-11, cuevasestrada2023breakingthemold pages 17-19)
Cell Type Primordial Germ Cell (CL:0000039) Cell of origin for TGCT. Latent pluripotency and defective epigenetic reprogramming in utero (arrested development) lead to GCNIS. (onorato2024rasmapksignalingpathway pages 3-5, onorato2024rasmitogenactivatedproteinkinase pages 2-4, onorato2024rasmitogenactivatedproteinkinase pages 1-2, nicu2024recentadvancementsin pages 2-4)
Cell Type Gonocyte (CL:0000016) Fetal germ cell stage; precursor to spermatogonia. GCNIS cells resemble arrested gonocytes/PGCs; retain expression of OCT4/NANOG. (eyben2023epigeneticregulationof pages 5-7, onorato2024rasmapksignalingpathway pages 3-5, onorato2024rasmitogenactivatedproteinkinase pages 2-4)
Cell Type GCNIS Cell (CL:0002542) Precursor lesion cell (Germ Cell Neoplasia In Situ). Dormant until puberty; unmethylated genome; evolves into seminoma or non-seminoma; retains 12p gain. (eyben2023epigeneticregulationof pages 5-7, onorato2024rasmapksignalingpathway pages 3-5, cuevasestrada2023breakingthemold pages 1-2, eyben2023epigeneticregulationof pages 7-9)
Cell Type Seminoma Cell (CL:0002167) Malignant cell of seminoma subtype. Resembles PGCs/gonocytes; highly sensitive to cisplatin/radiation; global DNA hypomethylation. (cuevasestrada2023breakingthemold pages 1-2, cuevasestrada2023breakingthemold pages 2-4, nicu2024recentadvancementsin pages 4-6)
Cell Type Embryonal Carcinoma Cell (CL:0002168) Stem-like cell of non-seminoma. Pluripotent (ESC-like); expresses CD30, SOX2, OCT4; can differentiate into teratoma/yolk sac; more aggressive. (eyben2023epigeneticregulationof pages 5-7, nicu2024recentadvancementsin pages 4-6)
Anatomy Testis (UBERON:0000473) Primary site of tumor origin. Location of GCNIS within seminiferous tubules; site of radical orchiectomy. (onorato2024rasmapksignalingpathway pages 3-5, onorato2024rasmitogenactivatedproteinkinase pages 1-2, krasic2023testiculargermcell pages 18-18)
Anatomy Seminiferous Tubule (UBERON:0001343) Structural unit of testis containing germ cells. GCNIS cells reside at the basement membrane of tubules prior to invasion. (krasic2023testiculargermcell pages 18-18)
Anatomy Retroperitoneal Lymph Node (UBERON:0002523) Primary site of metastatic spread. Common site for relapse/metastasis; site of RPLND surgery for residual mass. (belge2024detectionofrecurrence pages 1-2, yodkhunnatham2024micrornasintesticular pages 2-3, seales2024advancinggctmanagement pages 3-5)

Table: A structured overview of key genes, processes, biomarkers, drugs, and anatomical entities involved in TGCT development, progression, and treatment response, mapped to ontology concepts.

3.2 Figure: schematic of DNA methylation’s roles and clinical applications

Nicu et al. (May 2024) provide a schematic of DNA methylation’s mechanistic and clinical links in TGCT (DNMTs/TSG silencing, subtype methylation patterns, and biomarker/therapy applications) (nicu2024recentadvancementsin media 4d776599).

4. Biological processes (GO-oriented) disrupted in TGCT

The following GO-level biological processes are strongly supported by the evidence:

  1. Germ cell development and epigenetic reprogramming: male germline epigenetic reprogramming begins during PGC migration (May 2024 review), with errors proposed to contribute to emergence of GCNIS (nicu2024recentadvancementsin pages 2-4).
  2. DNA methylation / demethylation: global hypomethylation in GCNIS/seminoma vs hypermethylation in NSGCT/EC and differentiation (onorato2024rasmapksignalingpathway pages 5-7, nicu2024recentadvancementsin pages 4-6, eyben2023epigeneticregulationof pages 7-9).
  3. Cell cycle regulation and chromosomal instability: tetraploidization and aneuploidy; deregulated cyclins and CDK inhibitors (eyben2023epigeneticregulationof pages 5-7).
  4. RTK signaling and MAPK cascade: KIT→RAS→ERK as a recurrent driver and a germline survival pathway co-opted in tumorigenesis (onorato2024rasmitogenactivatedproteinkinase pages 5-7, onorato2024rasmitogenactivatedproteinkinase pages 2-4).
  5. DNA damage response and repair (NER/HR) and apoptosis: attenuated repair and strong apoptotic response explain cisplatin sensitivity; resistance arises via repair upregulation and apoptosis attenuation (cuevasestrada2023breakingthemold pages 6-8, koberle2024strongapoptoticresponse pages 1-2, cuevasestrada2023breakingthemold pages 8-10).
  6. Neddylation: contributes to cisplatin resistance by promoting degradation of tumor suppressors and impairing apoptosis (funke2023genomescalecrisprscreen pages 11-12).

5. Cellular components (GO-CC-oriented): where key processes occur

  • Nucleus/chromatin: DNA methylation and histone marks (H3K27me3 at SOX2 promoter; polycomb complex involvement) (eyben2023epigeneticregulationof pages 7-9).
  • Mitochondria: intrinsic apoptotic signaling via Bax translocation and cytochrome c release after cisplatin (koberle2024strongapoptoticresponse pages 1-2, koberle2024strongapoptoticresponse pages 8-9).
  • Plasma membrane / receptor complexes: KIT receptor signaling; Fas death receptor pathway (onorato2024rasmitogenactivatedproteinkinase pages 5-7, koberle2024strongapoptoticresponse pages 1-2).

6. Disease progression: sequence of events and stages

6.1 Developmental initiation → GCNIS

  • Initiation is “most likely… in utero” in PGCs/gonocytes (onorato2024rasmitogenactivatedproteinkinase pages 2-4).
  • GCNIS is composed of arrested PGCs failing to mature into gonocytes, expressing pluripotency markers and remaining dormant until puberty (cuevasestrada2023breakingthemold pages 1-2).

6.2 Puberty-associated outgrowth and genomic evolution

  • Chromosomal evolution includes i(12p) gain (>80%) and aneuploidy (onorato2024rasmitogenactivatedproteinkinase pages 2-4, cuevasestrada2023breakingthemold pages 2-4).
  • Early “tetraploidization is the first step” (eyben2023epigeneticregulationof pages 5-7).

6.3 Divergence to seminoma vs nonseminoma

  • Seminoma/GCNIS show PGC-like hypomethylation (onorato2024rasmapksignalingpathway pages 5-7, nicu2024recentadvancementsin pages 4-6).
  • EC/NSGCT show ESC-like methylation states and pluripotency networks (OCT4/SOX2/LIN28) enabling further lineage differentiation into teratoma/YST/choriocarcinoma (eyben2023epigeneticregulationof pages 5-7, cuevasestrada2023breakingthemold pages 1-2, nicu2024recentadvancementsin pages 4-6).

6.4 Metastasis/relapse and clinical course (statistics)

  • In a prospective surveillance cohort of 258 clinical stage I patients, relapse occurred in 15.1% (39/258) (Belge et al., Clinical Cancer Research; publication date Nov 2024; URL https://doi.org/10.1158/1078-0432.ccr-23-0730) (belge2024detectionofrecurrence pages 1-2).
  • Risk stratification reported: seminoma tumor size >4 cm relapse ~20%; nonseminoma with lymphovascular invasion relapse ~40–50%; nonseminoma without LVI relapse ~15% (belge2024detectionofrecurrence pages 1-2).
  • Broader review statement: “about 30% of patients on active surveillance will relapse” and the retroperitoneum is a common relapse site (Mar 2024 review) (seales2024advancinggctmanagement pages 3-5).

6.5 Treatment response and resistance

  • Metastatic TGCTs are “cured in over 80% of patients using cisplatin-based combination therapy” (Oct 2024 primary paper) (koberle2024strongapoptoticresponse pages 1-2).
  • Platinum-refractory disease: reported as approximately 15% (review; Jan 2024) (evmorfopoulos2024theimmunelandscape pages 1-2) and cisplatin resistance is also stated to occur in up to ~10–15% (May 2024 review) (nicu2024recentadvancementsin pages 2-4).

7. Phenotypic manifestations (HP-oriented) and mechanistic linkage

7.1 Clinical phenotypes (examples)

Evidence in this corpus focuses more on biomarkers and treatment response than presenting symptoms; nonetheless, TGCT presents commonly at stage I and is monitored with serum markers and imaging (belge2024detectionofrecurrence pages 1-2).

7.2 Biomarkers and pathophysiologic interpretation

Traditional serum tumor markers reflect differentiated lineage outputs and tumor burden but have major sensitivity limitations. - A 2024 biomarker review reports overall combined sensitivity of traditional markers AFP/β-hCG/LDH of “~50%” (sykes2024currentandevolving pages 1-2). - By histology, seminoma sensitivity is particularly limited (AFP ~2.3%, β-hCG 31%, LDH 28%; combined 46%) (sykes2024currentandevolving pages 1-2).

Circulating miRNAs (particularly miR-371a-3p) reflect active viable non-teratomatous TGCT biology. - Belge et al. (Nov 2024) report relapse detection AUC 0.993, sensitivity 100%, specificity 96.3%, PPV 83%, NPV 100% (belge2024detectionofrecurrence pages 1-2). - Reviews compile diagnostic performance across studies: e.g., Dieckmann cohort (n=616) sensitivity 91.8%, specificity 96.1%, AUC 0.97 (Feb 2024 review) (yodkhunnatham2024micrornasintesticular pages 3-5). - Limitation: miRNAs “cannot detect teratoma” (Dec 2024 review) (sykes2024currentandevolving pages 1-2).

8. Recent developments (prioritizing 2023–2024)

8.1 Whole-genome and evolutionary modeling advances

Recent WGS-based work in adult TGCT emphasizes correlations between genomic alterations and histologic diversification and immune disruption (Nature Communications 2024; metadata in search results; not extracted here for mechanistic quotes due to limited evidence snippet content in this run) (leathlobhair2024genomiclandscapeof). The strongest directly quotable WGS-linked mechanistic evidence in this run relates to early hallmark events (12p gain and tetraploidization) and subtype divergence (eyben2023epigeneticregulationof pages 5-7, cuevasestrada2023breakingthemold pages 2-4).

8.2 Epigenetic biomarkers and “epigenetic priming” strategies

  • DNA methylation-based classifiers/signatures are being developed for diagnosis, metastasis prediction, and therapy response (May 2024 review) (nicu2024recentadvancementsin pages 8-10).
  • Cisplatin resistance is increasingly framed as epigenetically mediated: “global remodeling of DNA methylation in cisplatin-resistant cells” with increased methylation and tumor suppressor downregulation (nicu2024recentadvancementsin pages 10-11).

8.3 Cisplatin resistance mechanisms: targetable nodes

  • Genome-scale CRISPR activation screening implicates neddylation/NAE1, and inhibition by MLN4924 (pevonedistat) “resulted in re-sensitisation of cisplatin-resistant cells” (Apr 2023 paper) (funke2023genomescalecrisprscreen pages 11-12).
  • Apoptosis and DNA repair phenotypes continue to be refined experimentally; a 2024 study demonstrates strong activation of both FAS-mediated and mitochondrial apoptosis after cisplatin, and that knockdown of p53/FAS increases resistance (koberle2024strongapoptoticresponse pages 1-2).

8.4 Clinical validation of miR-371a-3p for relapse detection (real-world implementation readiness)

  • Prospective multicenter surveillance data show superior relapse detection and the authors state “clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules” (Belge et al., 2024) (belge2024detectionofrecurrence pages 1-2).

9. Current applications and real-world implementations

9.1 Standard-of-care disease management linked to pathophysiology

  • Treatment relies on cisplatin-based chemotherapy (BEP-type regimens are referenced in epigenetic review) (nicu2024recentadvancementsin pages 2-4) and surgical management (orchiectomy; retroperitoneal mass resection) (evmorfopoulos2024theimmunelandscape pages 1-2).
  • High cure rates are attributed to inherent biology: limited DNA repair capacity and strong apoptotic propensity (cuevasestrada2023breakingthemold pages 6-8, koberle2024strongapoptoticresponse pages 1-2).

9.2 Biomarkers in use and emerging

  • Traditional STMs: AFP, β-hCG, LDH remain standard but have low sensitivity and specificity limitations (sykes2024currentandevolving pages 1-2, sykes2024currentandevolving pages 2-4).
  • Emerging/near-implementation: serum miR-371a-3p for diagnosis and relapse detection shows very high accuracy in prospective settings (belge2024detectionofrecurrence pages 1-2).

10. Expert opinions and analysis (authoritative syntheses)

Key expert-level synthesis points consistent across 2023–2024 reviews and supported by primary evidence: 1. TGCT as a developmental cancer: initiating lesion likely forms in utero and is shaped by germline epigenetic reprogramming failures (onorato2024rasmitogenactivatedproteinkinase pages 2-4, nicu2024recentadvancementsin pages 2-4). 2. Subtype biology is epigenetically encoded: seminoma/GCNIS resemble fetal germ cells with global hypomethylation; nonseminoma exhibits hypermethylation and ESC-like methylomes in EC (onorato2024rasmapksignalingpathway pages 5-7, nicu2024recentadvancementsin pages 4-6). 3. Curability is mechanistically tied to apoptosis and repair deficiency: cisplatin cures most patients because DNA repair is attenuated while apoptosis is readily triggered via p53/FAS and mitochondrial programs (cuevasestrada2023breakingthemold pages 6-8, koberle2024strongapoptoticresponse pages 1-2). 4. Resistance is multifactorial but increasingly targetable: epigenetic rewiring (H3K27me3 dynamics, DNMT3B, PRC2 axis) and proteostasis-related processes (neddylation) represent actionable nodes for combination strategies (cuevasestrada2023breakingthemold pages 17-19, funke2023genomescalecrisprscreen pages 11-12).

11. Evidence items (PMIDs, where available) and publication details

Note: The tool outputs in this run provided DOIs and URLs for the 2023–2024 papers but did not provide PMIDs for most items in the extracted text. Where PMIDs are required, they should be programmatically added from PubMed using DOI→PMID mapping in a downstream curation step. The following are directly evidenced here: - Cuevas-Estrada et al. Int J Mol Sci (Apr 2023). DOI: https://doi.org/10.3390/ijms24097873 (cuevasestrada2023breakingthemold pages 1-2, cuevasestrada2023breakingthemold pages 2-4, cuevasestrada2023breakingthemold pages 6-8, cuevasestrada2023breakingthemold pages 5-6, cuevasestrada2023breakingthemold pages 17-19) - von Eyben et al. Int J Mol Sci (Feb 2023). DOI: https://doi.org/10.3390/ijms24044148 (eyben2023epigeneticregulationof pages 5-7, eyben2023epigeneticregulationof pages 7-9) - Funke et al. Br J Cancer (Apr 2023). DOI: https://doi.org/10.1038/s41416-023-02247-5 (funke2023genomescalecrisprscreen pages 11-12) - Nicu et al. Biomedicines (May 2024). DOI: https://doi.org/10.3390/biomedicines12051041 (nicu2024recentadvancementsin pages 4-6, nicu2024recentadvancementsin pages 10-11, nicu2024recentadvancementsin pages 2-4, nicu2024recentadvancementsin media 4d776599) - Onorato et al. Life (Feb 2024). DOI: https://doi.org/10.3390/life14030327 (onorato2024rasmitogenactivatedproteinkinase pages 2-4, onorato2024rasmitogenactivatedproteinkinase pages 5-7, onorato2024rasmitogenactivatedproteinkinase pages 1-2, onorato2024rasmitogenactivatedproteinkinase pages 7-9) - Evmorfopoulos et al. Cancers (Jan 2024). DOI: https://doi.org/10.3390/cancers16020428 (evmorfopoulos2024theimmunelandscape pages 1-2) - Belge et al. Clinical Cancer Research (Nov 2024). DOI: https://doi.org/10.1158/1078-0432.ccr-23-0730 (belge2024detectionofrecurrence pages 1-2, belge2024detectionofrecurrence pages 2-3) - Travis et al. Journal of Clinical Oncology (Oct 2024). DOI: https://doi.org/10.1200/JCO.23.01099 (travis2024adolescentandyoung pages 1-3, travis2024adolescentandyoung pages 3-4) - Kberle et al. Int Urol Nephrol (Oct 2024). DOI: https://doi.org/10.1007/s11255-023-03825-5 (koberle2024strongapoptoticresponse pages 1-2, koberle2024strongapoptoticresponse pages 8-9)

12. Summary (knowledge-base style)

TGCT pathophysiology is best understood as a developmental malignancy of the male germline in which in utero-arising, epigenetically abnormal PGC/gonocyte-derived cells persist as GCNIS until puberty. Progression is driven by chromosomal instability—particularly 12p gain/i(12p)—and by dysregulated signaling (KIT/KITLG→RAS/MAPK, PI3K/AKT) and pluripotency programs (OCT4/SOX2/LIN28, NANOG) that distinguish seminoma (PGC-like, hypomethylated) from embryonal carcinoma/nonseminoma (ESC-like methylome and differentiation). Exceptional cisplatin curability is mechanistically linked to limited DNA repair and strong p53/FAS and mitochondrial apoptosis; resistant disease emerges in ~10–15% via enhanced repair, apoptosis suppression, and epigenetic/proteostasis rewiring. Biomarker practice is shifting from low-sensitivity serum proteins (AFP/β-hCG/LDH) toward circulating miRNAs (miR-371a-3p), supported by prospective evidence for relapse detection.

References

  1. (nicu2024recentadvancementsin pages 1-2): Alina-Teodora Nicu, Ileana Paula Ionel, Ileana Stoica, Liliana Burlibasa, and Viorel Jinga. Recent advancements in research on dna methylation and testicular germ cell tumors: unveiling the intricate relationship. Biomedicines, 12:1041, May 2024. URL: https://doi.org/10.3390/biomedicines12051041, doi:10.3390/biomedicines12051041. This article has 8 citations.

  2. (cuevasestrada2023breakingthemold pages 1-2): Berenice Cuevas-Estrada, Michel Montalvo-Casimiro, Paulina Munguia-Garza, Juan Alberto Ríos-Rodríguez, Rodrigo González-Barrios, and Luis A. Herrera. Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in tgct patients. International Journal of Molecular Sciences, 24:7873, Apr 2023. URL: https://doi.org/10.3390/ijms24097873, doi:10.3390/ijms24097873. This article has 8 citations.

  3. (onorato2024rasmitogenactivatedproteinkinase pages 2-4): Angelo Onorato, Eugenia Guida, Ambra Colopi, Susanna Dolci, and Paola Grimaldi. Ras/mitogen-activated protein kinase signaling pathway in testicular germ cell tumors. Life, 14:327, Feb 2024. URL: https://doi.org/10.3390/life14030327, doi:10.3390/life14030327. This article has 8 citations.

  4. (eyben2023epigeneticregulationof pages 5-7): Finn E. von Eyben, Karsten Kristiansen, Daniel S. Kapp, Rong Hu, Ovidiu Preda, and Francisco F. Nogales. Epigenetic regulation of driver genes in testicular tumorigenesis. International Journal of Molecular Sciences, 24:4148, Feb 2023. URL: https://doi.org/10.3390/ijms24044148, doi:10.3390/ijms24044148. This article has 12 citations.

  5. (cuevasestrada2023breakingthemold pages 2-4): Berenice Cuevas-Estrada, Michel Montalvo-Casimiro, Paulina Munguia-Garza, Juan Alberto Ríos-Rodríguez, Rodrigo González-Barrios, and Luis A. Herrera. Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in tgct patients. International Journal of Molecular Sciences, 24:7873, Apr 2023. URL: https://doi.org/10.3390/ijms24097873, doi:10.3390/ijms24097873. This article has 8 citations.

  6. (onorato2024rasmapksignalingpathway pages 5-7): Angelo Onorato, Eugenia Guida, Ambra Colopi, Susanna Dolci, and Paola Grimaldi. Ras/mapk signaling pathway in testicular germ cell tumors. Jan 2024. URL: https://doi.org/10.20944/preprints202401.1820.v1, doi:10.20944/preprints202401.1820.v1.

  7. (onorato2024rasmitogenactivatedproteinkinase pages 5-7): Angelo Onorato, Eugenia Guida, Ambra Colopi, Susanna Dolci, and Paola Grimaldi. Ras/mitogen-activated protein kinase signaling pathway in testicular germ cell tumors. Life, 14:327, Feb 2024. URL: https://doi.org/10.3390/life14030327, doi:10.3390/life14030327. This article has 8 citations.

  8. (nicu2024recentadvancementsin pages 4-6): Alina-Teodora Nicu, Ileana Paula Ionel, Ileana Stoica, Liliana Burlibasa, and Viorel Jinga. Recent advancements in research on dna methylation and testicular germ cell tumors: unveiling the intricate relationship. Biomedicines, 12:1041, May 2024. URL: https://doi.org/10.3390/biomedicines12051041, doi:10.3390/biomedicines12051041. This article has 8 citations.

  9. (eyben2023epigeneticregulationof pages 7-9): Finn E. von Eyben, Karsten Kristiansen, Daniel S. Kapp, Rong Hu, Ovidiu Preda, and Francisco F. Nogales. Epigenetic regulation of driver genes in testicular tumorigenesis. International Journal of Molecular Sciences, 24:4148, Feb 2023. URL: https://doi.org/10.3390/ijms24044148, doi:10.3390/ijms24044148. This article has 12 citations.

  10. (onorato2024rasmitogenactivatedproteinkinase pages 1-2): Angelo Onorato, Eugenia Guida, Ambra Colopi, Susanna Dolci, and Paola Grimaldi. Ras/mitogen-activated protein kinase signaling pathway in testicular germ cell tumors. Life, 14:327, Feb 2024. URL: https://doi.org/10.3390/life14030327, doi:10.3390/life14030327. This article has 8 citations.

  11. (onorato2024rasmapksignalingpathway pages 1-3): Angelo Onorato, Eugenia Guida, Ambra Colopi, Susanna Dolci, and Paola Grimaldi. Ras/mapk signaling pathway in testicular germ cell tumors. Jan 2024. URL: https://doi.org/10.20944/preprints202401.1820.v1, doi:10.20944/preprints202401.1820.v1.

  12. (onorato2024rasmitogenactivatedproteinkinase pages 7-9): Angelo Onorato, Eugenia Guida, Ambra Colopi, Susanna Dolci, and Paola Grimaldi. Ras/mitogen-activated protein kinase signaling pathway in testicular germ cell tumors. Life, 14:327, Feb 2024. URL: https://doi.org/10.3390/life14030327, doi:10.3390/life14030327. This article has 8 citations.

  13. (eyben2023epigeneticregulationof pages 21-22): Finn E. von Eyben, Karsten Kristiansen, Daniel S. Kapp, Rong Hu, Ovidiu Preda, and Francisco F. Nogales. Epigenetic regulation of driver genes in testicular tumorigenesis. International Journal of Molecular Sciences, 24:4148, Feb 2023. URL: https://doi.org/10.3390/ijms24044148, doi:10.3390/ijms24044148. This article has 12 citations.

  14. (cuevasestrada2023breakingthemold pages 8-10): Berenice Cuevas-Estrada, Michel Montalvo-Casimiro, Paulina Munguia-Garza, Juan Alberto Ríos-Rodríguez, Rodrigo González-Barrios, and Luis A. Herrera. Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in tgct patients. International Journal of Molecular Sciences, 24:7873, Apr 2023. URL: https://doi.org/10.3390/ijms24097873, doi:10.3390/ijms24097873. This article has 8 citations.

  15. (nicu2024recentadvancementsin pages 10-11): Alina-Teodora Nicu, Ileana Paula Ionel, Ileana Stoica, Liliana Burlibasa, and Viorel Jinga. Recent advancements in research on dna methylation and testicular germ cell tumors: unveiling the intricate relationship. Biomedicines, 12:1041, May 2024. URL: https://doi.org/10.3390/biomedicines12051041, doi:10.3390/biomedicines12051041. This article has 8 citations.

  16. (nicu2024recentadvancementsin pages 2-4): Alina-Teodora Nicu, Ileana Paula Ionel, Ileana Stoica, Liliana Burlibasa, and Viorel Jinga. Recent advancements in research on dna methylation and testicular germ cell tumors: unveiling the intricate relationship. Biomedicines, 12:1041, May 2024. URL: https://doi.org/10.3390/biomedicines12051041, doi:10.3390/biomedicines12051041. This article has 8 citations.

  17. (cuevasestrada2023breakingthemold pages 17-19): Berenice Cuevas-Estrada, Michel Montalvo-Casimiro, Paulina Munguia-Garza, Juan Alberto Ríos-Rodríguez, Rodrigo González-Barrios, and Luis A. Herrera. Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in tgct patients. International Journal of Molecular Sciences, 24:7873, Apr 2023. URL: https://doi.org/10.3390/ijms24097873, doi:10.3390/ijms24097873. This article has 8 citations.

  18. (funke2023genomescalecrisprscreen pages 11-12): Kai Funke, Ulf Einsfelder, Aylin Hansen, Lena Arévalo, Simon Schneider, Daniel Nettersheim, Valentin Stein, and Hubert Schorle. Genome-scale crispr screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours. British Journal of Cancer, 128:2270-2282, Apr 2023. URL: https://doi.org/10.1038/s41416-023-02247-5, doi:10.1038/s41416-023-02247-5. This article has 19 citations and is from a domain leading peer-reviewed journal.

  19. (cuevasestrada2023breakingthemold pages 6-8): Berenice Cuevas-Estrada, Michel Montalvo-Casimiro, Paulina Munguia-Garza, Juan Alberto Ríos-Rodríguez, Rodrigo González-Barrios, and Luis A. Herrera. Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in tgct patients. International Journal of Molecular Sciences, 24:7873, Apr 2023. URL: https://doi.org/10.3390/ijms24097873, doi:10.3390/ijms24097873. This article has 8 citations.

  20. (koberle2024strongapoptoticresponse pages 1-2): Beate Köberle, Svetlana Usanova, Andrea Piee-Staffa, Ulrike Heinicke, Philipp Clauss, Anamaria Brozovic, and Bernd Kaina. Strong apoptotic response of testis tumor cells following cisplatin treatment. International Urology and Nephrology, 56:1007-1017, Oct 2024. URL: https://doi.org/10.1007/s11255-023-03825-5, doi:10.1007/s11255-023-03825-5. This article has 2 citations and is from a peer-reviewed journal.

  21. (cuevasestrada2023breakingthemold pages 29-30): Berenice Cuevas-Estrada, Michel Montalvo-Casimiro, Paulina Munguia-Garza, Juan Alberto Ríos-Rodríguez, Rodrigo González-Barrios, and Luis A. Herrera. Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in tgct patients. International Journal of Molecular Sciences, 24:7873, Apr 2023. URL: https://doi.org/10.3390/ijms24097873, doi:10.3390/ijms24097873. This article has 8 citations.

  22. (cuevasestrada2023breakingthemold pages 5-6): Berenice Cuevas-Estrada, Michel Montalvo-Casimiro, Paulina Munguia-Garza, Juan Alberto Ríos-Rodríguez, Rodrigo González-Barrios, and Luis A. Herrera. Breaking the mold: epigenetics and genomics approaches addressing novel treatments and chemoresponse in tgct patients. International Journal of Molecular Sciences, 24:7873, Apr 2023. URL: https://doi.org/10.3390/ijms24097873, doi:10.3390/ijms24097873. This article has 8 citations.

  23. (koberle2024strongapoptoticresponse pages 8-9): Beate Köberle, Svetlana Usanova, Andrea Piee-Staffa, Ulrike Heinicke, Philipp Clauss, Anamaria Brozovic, and Bernd Kaina. Strong apoptotic response of testis tumor cells following cisplatin treatment. International Urology and Nephrology, 56:1007-1017, Oct 2024. URL: https://doi.org/10.1007/s11255-023-03825-5, doi:10.1007/s11255-023-03825-5. This article has 2 citations and is from a peer-reviewed journal.

  24. (onorato2024rasmapksignalingpathway pages 3-5): Angelo Onorato, Eugenia Guida, Ambra Colopi, Susanna Dolci, and Paola Grimaldi. Ras/mapk signaling pathway in testicular germ cell tumors. Jan 2024. URL: https://doi.org/10.20944/preprints202401.1820.v1, doi:10.20944/preprints202401.1820.v1.

  25. (sykes2024currentandevolving pages 1-2): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 13 citations.

  26. (belge2024detectionofrecurrence pages 1-2): Gazanfer Belge, Cansu Dumlupinar, Tim Nestler, Markus Klemke, Peter Törzsök, Emanuela Trenti, Renate Pichler, Wolfgang Loidl, Yue Che, Andreas Hiester, Cord Matthies, Martin Pichler, Pia Paffenholz, Luis Kluth, Mike Wenzel, Jörg Sommer, Julia Heinzelbecker, Philipp Schriefer, Alexander Winter, Friedemann Zengerling, Mario Wolfgang Kramer, Marie Lengert, Jana Frey, Axel Heidenreich, Christian Wülfing, Arlo Radtke, and Klaus-Peter Dieckmann. Detection of recurrence through microrna-371a-3p serum levels in a follow-up of stage i testicular germ cell tumors in the drks-00019223 study. Clinical Cancer Research, 30:404-412, Nov 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-0730, doi:10.1158/1078-0432.ccr-23-0730. This article has 33 citations and is from a highest quality peer-reviewed journal.

  27. (seales2024advancinggctmanagement pages 2-3): Crystal L Seales, Dhruv Puri, Nuphat Yodkhunnatham, Kshitij Pandit, Kit Yuen, Sarah Murray, Jane Smitham, John T Lafin, and Aditya Bagrodia. Advancing gct management: a review of mir-371a-3p and other mirnas in comparison to traditional serum tumor markers. Cancers, Mar 2024. URL: https://doi.org/10.3390/cancers16071379, doi:10.3390/cancers16071379. This article has 10 citations.

  28. (sykes2024currentandevolving pages 2-4): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 13 citations.

  29. (seales2024advancinggctmanagement pages 3-5): Crystal L Seales, Dhruv Puri, Nuphat Yodkhunnatham, Kshitij Pandit, Kit Yuen, Sarah Murray, Jane Smitham, John T Lafin, and Aditya Bagrodia. Advancing gct management: a review of mir-371a-3p and other mirnas in comparison to traditional serum tumor markers. Cancers, Mar 2024. URL: https://doi.org/10.3390/cancers16071379, doi:10.3390/cancers16071379. This article has 10 citations.

  30. (belge2024detectionofrecurrence pages 2-3): Gazanfer Belge, Cansu Dumlupinar, Tim Nestler, Markus Klemke, Peter Törzsök, Emanuela Trenti, Renate Pichler, Wolfgang Loidl, Yue Che, Andreas Hiester, Cord Matthies, Martin Pichler, Pia Paffenholz, Luis Kluth, Mike Wenzel, Jörg Sommer, Julia Heinzelbecker, Philipp Schriefer, Alexander Winter, Friedemann Zengerling, Mario Wolfgang Kramer, Marie Lengert, Jana Frey, Axel Heidenreich, Christian Wülfing, Arlo Radtke, and Klaus-Peter Dieckmann. Detection of recurrence through microrna-371a-3p serum levels in a follow-up of stage i testicular germ cell tumors in the drks-00019223 study. Clinical Cancer Research, 30:404-412, Nov 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-0730, doi:10.1158/1078-0432.ccr-23-0730. This article has 33 citations and is from a highest quality peer-reviewed journal.

  31. (yodkhunnatham2024micrornasintesticular pages 3-5): Nuphat Yodkhunnatham, Kshitij Pandit, Dhruv Puri, Kit L. Yuen, and Aditya Bagrodia. Micrornas in testicular germ cell tumors: the teratoma challenge. International Journal of Molecular Sciences, 25:2156, Feb 2024. URL: https://doi.org/10.3390/ijms25042156, doi:10.3390/ijms25042156. This article has 27 citations.

  32. (evmorfopoulos2024theimmunelandscape pages 1-2): Konstantinos Evmorfopoulos, Konstantinos Marsitopoulos, Raphael Karachalios, Athanasios Karathanasis, Konstantinos Dimitropoulos, Vassilios Tzortzis, Ioannis Zachos, and Panagiotis J. Vlachostergios. The immune landscape and immunotherapeutic strategies in platinum-refractory testicular germ cell tumors. Cancers, 16:428, Jan 2024. URL: https://doi.org/10.3390/cancers16020428, doi:10.3390/cancers16020428. This article has 6 citations.

  33. (krasic2023testiculargermcell pages 18-18): Jure Krasic, Lucija Skara Abramovic, Marta Himelreich Peric, Vedran Vanjorek, Marko Gangur, Dragana Zovko, Marina Malnar, Silvija Masic, Alma Demirovic, Bernardica Juric, Monika Ulamec, Marijana Coric, Davor Jezek, Tomislav Kulis, and Nino Sincic. Testicular germ cell tumor tissue biomarker analysis: a comparison of human protein atlas and individual testicular germ cell tumor component immunohistochemistry. Cells, 12:1841, Jul 2023. URL: https://doi.org/10.3390/cells12141841, doi:10.3390/cells12141841. This article has 5 citations.

  34. (yodkhunnatham2024micrornasintesticular pages 2-3): Nuphat Yodkhunnatham, Kshitij Pandit, Dhruv Puri, Kit L. Yuen, and Aditya Bagrodia. Micrornas in testicular germ cell tumors: the teratoma challenge. International Journal of Molecular Sciences, 25:2156, Feb 2024. URL: https://doi.org/10.3390/ijms25042156, doi:10.3390/ijms25042156. This article has 27 citations.

  35. (nicu2024recentadvancementsin media 4d776599): Alina-Teodora Nicu, Ileana Paula Ionel, Ileana Stoica, Liliana Burlibasa, and Viorel Jinga. Recent advancements in research on dna methylation and testicular germ cell tumors: unveiling the intricate relationship. Biomedicines, 12:1041, May 2024. URL: https://doi.org/10.3390/biomedicines12051041, doi:10.3390/biomedicines12051041. This article has 8 citations.

  36. (nicu2024recentadvancementsin pages 8-10): Alina-Teodora Nicu, Ileana Paula Ionel, Ileana Stoica, Liliana Burlibasa, and Viorel Jinga. Recent advancements in research on dna methylation and testicular germ cell tumors: unveiling the intricate relationship. Biomedicines, 12:1041, May 2024. URL: https://doi.org/10.3390/biomedicines12051041, doi:10.3390/biomedicines12051041. This article has 8 citations.

  37. (travis2024adolescentandyoung pages 1-3): Lois B. Travis, Darren R. Feldman, Chunkit Fung, Jenny N. Poynter, Michelle Lockley, and A. Lindsay Frazier. Adolescent and young adult germ cell tumors: epidemiology, genomics, treatment, and survivorship. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, pages JCO2301099, Oct 2024. URL: https://doi.org/10.1200/jco.23.01099, doi:10.1200/jco.23.01099. This article has 29 citations.

  38. (travis2024adolescentandyoung pages 3-4): Lois B. Travis, Darren R. Feldman, Chunkit Fung, Jenny N. Poynter, Michelle Lockley, and A. Lindsay Frazier. Adolescent and young adult germ cell tumors: epidemiology, genomics, treatment, and survivorship. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, pages JCO2301099, Oct 2024. URL: https://doi.org/10.1200/jco.23.01099, doi:10.1200/jco.23.01099. This article has 29 citations.